Updates on Ramantamig, a Myeloma Trispecific Antibody | Mark Wildgust, PhD

I'm Mark Wildgust. I'm the Vice President of Global Medical Affairs at Johnson & Johnson. And I'm here in Orlando at ASH. It is an amazing time and I'm excited to be talking a little bit about one of our new investigational agents, Romantomic, also has a J&J name, J&J 5322. We presented some data on Romantomic earlier this year at both ASCO and EHA, which is really its coming out. And this new molecule that we have at Johnson & Johnson, we think that this is that next leap forward in terms of immunotherapy. I know everyone's excited about Tech Bailey and Talvay and there's a late breaker here tomorrow, you know, Majestic 3, but that next generation of immunotherapy is really that ability to target two different targets on a myeloma cell. And that's what Romantomic is all about. And at Johnson & Johnson, we've redesigned a new type of molecule. It's one molecule with two targets targeting something that we call GPRC5D and BCMA. And those are commonly expressed on myeloma cells. And the Romantomic molecule then grabs those T cells and then redirects them to the myeloma cells. We presented the first data at ASCO and EHA and we're presenting updated data here at the ASH meeting. We've now got 18 months worth of follow-up. I think one of the most important things for this medicine is that we've really focused on optimizing it for the patient community. We've made it simpler with just one step up dose. We can go right into monthly dosing. And we've really redesigned how Romantomic grabs hold of those myeloma cells. So it actually makes the profile potentially even better. So we seem to see a better profile in terms of safety, perhaps less infections, perhaps less of the taste changes that we see with targeting GPRC5D. We really see some amazing efficacy. We're seeing 100% response rate in those patients who have never seen a BCMA or GPRC5D agent before. And those patients go into MRD negativity extremely quickly. Then here at the meeting we're reporting long-term follow-up. And what we see is that we see that the CR rate is deepening from 70% at ASCO and ASH earlier this year to almost 90% now in terms of that depth of response. But we also see that progression-free survival in this triple class refractory group of patients. 92% of those patients are progression-free at a year. And it really portends to really something that is a deep, durable regimen, but also that tolerability I think is so important. Romantimig right now is delivered one step-up dose. And then we give it as one dose every four weeks at 100 milligrams. And it's delivered subcutaneously. So it's really simple and straightforward for the patient. A simple subcutaneous push once a month. And so that really allows those patients really to have that ability to get their myeloma therapy and potentially be able to kind of go back to their lives as well. I think one of the things that we hear from patients a lot is this worry about cytokine release syndrome, which is one of those things where you might feel a bit funny after having those infusions. The great thing is that we're really seeing low rates of cytokine release, the grade 2s or higher. The grade 1s are fever, which you can commonly manage with Tylenol at home. But the grade 2 rate is actually quite low at 15%. So that's very promising as well. So at J&J, we've been innovating in myeloma for more than 20 years. I remember when I started working in myeloma, we were thinking about chemotherapy. Now we're really redesigning molecules that are immunotherapy based. And at J&J, romantimig is one of those molecules that we're extremely excited about because we think it's that next generation of treatment for patients.